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Objective. To evaluate results, complications and mortality following percutaneous transluminal renal angioplasty
(PTRA) and open surgical revascularisation for renovascular disease.
Methods. A retrospective evaluation of 381 renovascular patients (median age 64, range 9–99 years, 152 women) treated at
Malmo¨ University Hospital during 1987–1996. Two hundred and sixty-two (69%) of the patients were treated with PTRA,
106 (28%) with open revascularisation.
Results. Thirty-day mortality was 2% in the PTRA group and 9% after open surgery (p , 0.001). There were no
differences between groups concerning the number of re-do procedures, but first re-do was performed after seven (IQR 3–14)
months in the PTRA group, and after 15 (IQR 10–44) months after open revascularisation (p , 0.0001). After a median
follow-up of 4 months (IQR 0–13) systolic and diastolic blood pressure (BP) had decreased (p , 0.0001) in both groups. The
number of antihypertensive drugs was reduced (p , 0.0001) and S-creatinine levels were unchanged in both groups. Long-
time survival assessed with log-rank analysis was better (p , 0.01) in the PTRA group. The risk ratio for death with open
revascularisation was 1.69 (p , 0.01).
Conclusions. In this retrospective comparison, PTRA was as effective as open revascularisation, with lower complication
rate and lower early and long-time mortality, but with shorter time to first re-do.
Key Words: Renal artery stenosis; PTRA; Open renal vascularisation; Long-term follow-up.
Introduction
Renal artery stenosis is known to cause hypertension
or renal insufficiency, or both. Natural history studies
have shown progressive atherosclerotic disease in
44–49% of individuals with atherosclerotic renal
artery stenosis, even a little higher if associated with
aortic atherosclerotic disease. Occlusion occurs in
7–16% during a 5–7 year follow-up, the risk of
occlusion being particularly great in stenosis . 75%.1,2
In fibromuscular dysplasia stenosis is progressive in
34%.1
Indications for revascularisation are to control
hypertension, improve renal function, or prevent
renal failure, and occasionally ‘flash’ pulmonary
oedema, especially in single renal patients. The
treatment of choice in such cases was traditionally
and remains so in certain centres—open surgery,3 – 11
but during the last decade, percutaneous transluminal
renal angioplasty (PTRA) has emerged as an alterna-
tive treatment.10,12 – 17
Weibull et al., proposed the following conditions for
accepting PTRA as a primary method for revascular-
isation.10 ‘Technical success . 80%, two-year primary
patency . 75%, two-year secondary patency the same
as for surgery, and the same results on blood pressure
and renal function as for open surgery’.
As these conditions were fulfilled, PTRA was
recommended as first choice of treatment at our
institution.10 The intention of the present study was
to follow up the clinical practice, which, with growing
experience, has emerged from this recommendation,
and evaluate the available methods for treatment of
renal artery stenosis, i.e. open revascularisation and
PTRA, in a long-term perspective. Complications,
mortality, and short- and long-term results for the
different methods are described and compared for all
Eur J Vasc Endovasc Surg 27, 151–156 (2004)
doi: 10.1016/j.ejvs.2003.10.009, available online at http://www.sciencedirect.com on
*Corresponding author. Dr Bengt Lindblad, Department of Vascular
and Renal Diseases, Lund University, Malmo¨ University Hospital,
S-205 02 Malmo¨, Sweden.
1078–5884/000151 + 06 $35.00/0 q 2003 Elsevier Ltd. All rights reserved.
patients treated at Malmo¨ University Hospital in
1987–96.
Material and Methods
Methods
All 381 patients that underwent surgical or endovas-
cular procedures for renovascular disease at Malmo¨
University Hospital during 1987–1996 were identified
and patient files from departments involved in the
management were reviewed. Complementary infor-
mation from the Swedish Vascular Registry (Swed-
vasc) was obtained for 297 (78%) patients and from a
patient questionnaire (in average 7.1 years after
treatment) in 145 patients. Regarding BP and s-
creatinine only data from hospital records were
utilised. Data on survival for all patients were
obtained in 2001.
Patient material
Of the 381 patients (median age 64, range 9–99 years,
152 women) 262 (69%) were primarily treated with
PTRA, 106 (28%) with open revascularisation, of
which 33 (31%) had simultaneous measures against
aneurysm or occlusive disease of the abdominal aorta.
Open revascularisation was normally a transverse
arteriotomy, endarterectomy and patch closure if not
aortic surgery was needed when a 5–6 mm dacron or
PTFE by-pass with end-to-end anastomosis to the
renal artery was used. The remainder underwent
nephrectomy ðn ¼ 11Þ; division on the crus dia-
phragma ðn ¼ 1Þ and correction of a venous malfor-
mation ðn ¼ 1Þ: Of the 262 patients undergoing PTRA,
24 patients during the last two years studied had stent
placement (Table 1).
Open revascularisation dominated during 1987–90,
accounting for 60% of primary treatments, whereas
PTRA accounted for . 90% during 1993–96. The
cause of stenosis was atherosclerosis in 328 (86%)
patients (median age 65 years, 118 women) and
fibromuscular dysplasia (FMD) in 40 (10%) patients
(median age 40 years, 31 (78%) treated with PTRA,
34 women, Table 1). Five patients (three treated with
PTRA) had renal transplants. Other diagnoses were
venous and arterial malformation, radiation injury,
external compression of the renal artery by crus
diaphragma and Tachayasu’s disease. Bilateral treat-
ment was performed in 138 (36%) patients (Table 1).
The main indication for treatment were hyperten-
sion and renal function only in 17 (6%) in the PTRA-
group and 10 (9%) in the open revascularized group.
Clearance was not regularly determined. Risk factors
such as smoking, diabetes, hyperlipidemia, and
occurrence of earlier vascular operations, amputa-
tions, and cardiovascular or cerebrovascular disease
were insufficiently recorded, but when reported, there
were no differences between the groups.
Renal diseases, such as chronic glomerulonephritis,
diabetic nephropathy, polycystic kidneys etc.,
occurred in seven (3%) patients treated with PTRA
and in two (2%) openly treated patients, nephrosclero-
sis in one patient each.
All secondary procedures aiming at improving
renal artery flow after the initial treatment, also
including the contralateral renal artery, was con-
sidered as a re-do procedure.
Definitions of outcome
Effects on blood pressure were regarded as:18
Cure—diastolic BP , 90 mmHg and systolic
BP , 140 mmHg, off antihypertensive medication.
Improvement—diastolic BP , 90 mmHg and/or
systolic BP , 140 mmHg on the same or reduced
number of medications or a reduction in diastolic BP
by at least . 15 mmHg with the same or a reduced
number of medications.
Failure—no change or inability to meet the criteria
for cure or improvement.
Renal function was regarded as:
Improvement—s-creatinine was reduced by $ 20%.
Stabilisation—s-creatinine changed by , 20%.
Failure—s-creatinine increased by # 20%.
Table 1. Patient material, n (%) or median and range.
PTRA ðn ¼ 262Þ Open revascularisation ðn ¼ 106Þ Nephrectomy ðn ¼ 11Þ Other operation ðn ¼ 2Þ
Sex (M/F) 148/114 69/37 7/4 2/0
Age (years) 65 (9–99) 64 (9–84) 62 (52–73) 19 (17–21)
Atherosclerotic stenosis 231 (88) 86 (81) 11 (100) 0 (0)
Fibromuscular dysplasia 31 (12) 9 (8) 0 (0) 0 (0)
Bilateral intervention 99 (38) 39 (37) 0 (0) 0 (0)
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Statistical analysis
Results are reported as median and interquartile
range. Comparisons between patients undergoing
PTRA and reconstructive surgery were made with
the Mann–Whitney U-test or the Chi2 test, and
comparisons within groups with the Wilcoxon’s
signed rank test. Long-time survival curve was
estimated according to Kaplan–Meier, and the com-
parison between groups was made with log-rank
analysis. Risk ratio for death was evaluated with Cox
proportional regression analysis. Because of the
limited number of patients undergoing nephrectomy
and other operations, no statistical calculations were
made in these two groups. P values , 0.05 were
considered significant. Stat View 4.5 (Abacus Concepts
Inc., Berkeley, CA, USA) was used for the statistical
calculations.
Results
Early mortality and complications
Thirty-day mortality was five (2%) in the PTRA group
and 10 (9%) after open surgery ðp , 0:0001Þ: Recon-
structive complications were recorded or denied for all
patients during hospital stay but 30 day follow-up
data was obtained for 266 (70%) patients, 164 (63%) in
the PTRA group and 92 (87%) openly reconstructed
(Table 2). Infection was more common among patients
undergoing open reconstruction ðp , 0:05Þ: There
were no differences between groups concerning the
number of general complications (Table 3). The over-
all procedural complication rate was 9% in the PTRA
group and 22% among openly reconstructed patients
ðp , 0:05Þ: Within the open group, the complication
rate was significantly ðp , 0:05Þ higher when com-
bined renal and aortic reconstruction was done, 11/33
(35%) compared with 12/73 (15%) when only renal
artery reconstruction was made.
Early adverse results (deterioration or death within
a month) occurred in 28 patients treated with PTRA
(10%), 14 treated with open renal artery surgery (19%)
and five patients treated with aortic and renal surgery
(15%).
Blood pressure and renal function
Data on BP, s-creatinine and the number of antihy-
pertensive drugs could be obtained from patient files
for up to median four (IQR 0–14) months. Both
systolic and diastolic BP decreased ðp , 0:0001Þ in
both patients treated with PTRA (from 185 (168–
200)/100 (90 – 110) to 150 (140 – 170)/85 (80 –
90) mmHg) and open revascularisation (from 180
(160–202)/100 (90–110) to 150 (140–170)/90 (80–
90) mmHg). Moreover, the number of antihyperten-
sive drugs was significantly ðp , 0:0001Þ reduced from
2 (2–3) to 2 (1–3) in the PTRA group, and from 2 (2–3)
to 1 (1–2) in the openly revascularised group. The s-
creatinine levels, on the other hand, were unchanged,
123 (92–172) and 115 (90–172) mmol in the PTRA
group, and 125 (100–180) and 125 (98–197) mmol in
the openly revascularised group.
When the results were categorized as above, benefit
(cure or improvement) regarding hypertension was
achieved in 172 (66%) patients treated with PTRA after
an average of 1.4 procedures per patient, and in 64
(60%) patients undergoing open revascularisation
after 1.3 procedures per patient. Of those categorised
as failure regarding control of hypertension 41 out of
90 PTRA-patients and 26 out of 52 open revascularised
patients had there antihypertensive treatment
reduced. Renal function was improved or stabilised
for 217 PTRA-patients (83%) and failure was seen in 45
(17%). For open revascularisation renal function was
improved or stabilised for 68 patients (64%) and
failure noted for 38 patients (36%) ðp , 0:001Þ:
Late deterioration was most common after open
revascularisation without aortic surgery (11%, 2.25
procedures per patient) to be compared with PTRA
Table 2. Re-dos and reconstructive complications (median and IQR or n (%)).
PTRA ðn ¼ 262Þ Open revascularisation ðn ¼ 106Þ
Number of re-do procedures 108 30*
Number of patients needing re-do (%) 75 (29) 21 (20)
Number of patients needing . 1 re-do 34 (13) 9 (8)
Time to 1: st re-do (months) 7 (3–14) 15 (10–44)**
Reconstructive complications PTRA (30 day reported for 164) Open revascularisation (30 day reported for 92)
Bleeding/haematoma 4 (2) 7 (8)
Occlusion/thrombosis 7 (4) 6 (6)
Infection 0 (0) 3 (3)*
Distal embolisation 2 (1) 2 (2)
*p , 0:05 compared with the PTRA group, **p , 0:0001 compared with the PTRA group.
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(8%) and open revascularisation with aortic surgery
(6%), both groups at 1.5 procedures per patient.
Re-do procedures (Table 2)
The number of re-do procedures, but not the number
of patients undergoing re-do, was significantly higher
in the PTRA group ðp , 0:05; Table 2). Furthermore,
the first re-do was performed after seven (3–14)
months in the PTRA group, compared with 15 (10–
44) months after open revascularisation ðp , 0:0001Þ:
Of the 75 PTRA-patients requiring a re-do 59 had re-do
PTRA (79%), and of the 21 open revascularised
patients requiring re-do 14 had re-do PTRA (67%).
Those requiring more than one re-do procedure had
repeated re-do with PTRA in 32/33 PTRA-patients
(92%) versus 7/9 open revascularised patients (75%).
Long term mortality (Fig. 1)
Long-time survival was significantly ðp , 0:01Þ better
in the PTRA group (Fig. 1), with a risk ratio for death
of 1.69 ðp , 0:01Þ in the openly reconstructed group.
The number of patients under observation were:
Number of
observation
years
Number of
observed
PTRA patients
Number of
observed open
revascularisation
patients
0 262 106
2 226 84
4 200 73
6 142 62
8 81 54
10 42 40
12 22 23
Discussion
In our analysis PTRA appears to be as effective as open
surgery for the treatment of isolated renal artery
stenosis. In addition, mortality for PTRA-treated
patients in the present population was reduced both
at 30 days and in long-term follow-up. Moreover, the
risk of deterioration was significantly less for PTRA-
treated, and the difference in the number of re-do
procedures—required to achieve the desired result–
was not different as presumed. A major flaw and
source for bias in this study is that the majority open
surgical patients were treated in the 80s and the
majority of PTRA-patients in the 90s. A simple
analysis of risk factors and patient’s characteristics
does not reveal any major differences between the
groups.
Procedural mortality was 2% for PTRA and 9% for
open revascularisation ðp . 0:01Þ: A number of other
studies support this difference. In large studies open
Table 3. General complications and mortality (n (%)).
General complications PTRA ðn ¼ 262Þ (30 day reported for 143) Open revascularisation ðn ¼ 106Þ (30 day reported for 96)
Renal complications 15 (9) 12 (12)
Cerebrovascular complications 3 (2) 1 (1)
Cardiac complications 3 (2) 4 (4)
Multi-organ failure 0 (0) 2 (2)
Pulmonary complications 1 (1) 2 (2)
Sepsis 0 (0) 1 (1)
Intensive care . 5 days 1 (1) 4 (4)
Mortality PTRA ðn ¼ 262Þ Open revascularisation ðn ¼ 106Þ
30-day mortality 5 (2) 10 (9)**
*p , 0:05 compared with the PTRA group, **p , 0:001 compared with the PTRA group.
Fig. 1. Kaplan–Meier long-time survival curve for patients
after PTRA (n ¼ 262; solid line) and after open reconstruc-
tion (n ¼ 106; dotted line). Yearly assessments of survival.
P , 0:01 for difference between groups.
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revascularisation has shown a 30-day mortality of
5.5–7.3%, also including a large proportion of patients
undergoing subsequent aortic surgery as well.3,5 This
has to be compared with the reported 30-day
postprocedural PTRA mortality of 0–1.5%,15,18,20
corresponding well with our results. Thus, PTRA has
lower procedural morbidity/mortality. With today’s
refined endovascular techniques, if combined aortic
and renal disease is seen, optimisation of the renal
arteries before aortic reconstruction seems preferable.
Even in patients with aneurysm, we would advocate
to have stenosis of the renal arteries endovascularly
dilated, and if required, stented prior to surgery. At
least theoretically, an optimised renal function should
decrease the operative risk.
In the PTRA group the long-time survival was 74%
at five years and 64% at 10 years corresponding to a
five-year survival of 64% and 10-year of 45% in the
open revascularised group. Survival in other large
surgically treated groups with equal age distribution
has been reported to be 60% at 38 months3 and 71% at
5 years.5 In other studies of PTRA a four-year survival
of 74% was reported,21 however, Paulsen and co-
workers found a five-year survival of only 58%.15
Thus, our finding is difficult to explain and not entirely
supported by other reports. It is, though, very difficult
to compare figures from different institutions. The
same selection criteria for treatment were used during
the analysed period in our institution, indicating that
our results might well be an important finding.
Re-do procedures were done earlier after PTRA
than after open surgery, which may partly be due to re-
dos being more readily expected and accepted after
PTRA. Moreover, many of our patients were followed
with routine control angiography,14 which in some
cases may have led to re-intervention without clinical
signs of re-stenosis. Additionally, patients with bilat-
eral disease often had their endovascular treatment
staged in two procedures adding to a higher incidence
of re-do procedures in the PTRA group as well, since
also procedures to the contralateral kidney were
considered as re-dos. Further improved results using
stents especially for ostial lesions have been
reported.19 – 22
Re-dos were concentrated to a fraction of the
population. In order to choose the proper first line
treatment, individualise follow-up and prevent recur-
rences, it would be valuable to further characterise
those more likely to need a re-do procedure. Orig-
inally, routine control angiography was done after 3–6
months. But with growing experience a less rigorous
practice has emerged, and our study comprises mainly
patients managed according to this practice. We
believe that patients with a remaining pressure
gradient after a PTRA have a three to four times
increased risk of developing re-stenosis and only this
group, nowadays, routinely undergoes control
angiography.
Hypertension can often be successfully managed
with modern antihypertensive drugs and, therefore,
surgical or endovascular intervention has been ques-
tioned.23 However, as secondary hypertension, includ-
ing renovascular hypertension often features a blunted
nocturnal fall in blood pressure,24 it is important to
reduce nocturnal blood pressure, to avoid increased
workload for the heart causing increased long-term
cardiovascular morbidity/mortality. Moreover, low-
ering the blood pressure with effective medical
therapy in a patient with a significant stenosis might
reduce renal blood-flow, leading to hypoperfusion and
risk of ischemic atrophy or even infarction. The main
problem, therefore, seems to be to evaluate when a
renal artery stenosis is of haemodynamic importance
and should be treated more aggressively. The cur-
rently ongoing studies ASTRAL and STAR will be
important to elucidate which renal artery stenosis
should be selected for treatment, but long-term follow-
up seems to be needed for the evaluation of morbid-
ity/mortality and what type of treatment that will be
optimal.
Clinical criteria are not sufficient to select patients
for renal artery treatment. Renogram and duplex
scanning are not sensitive enough. MRA and CT
angiography are under rapid improvement, and will
probably be beneficial screening tools for tomorrow.
Evaluation of the degree of stenosis from angiography
may be insufficient. During the last 10-year period, we
have partially based our judgement on treatment or
not on pressure recordings during angiography,
comparing the pressure in the aorta and in the renal
arteries, and have found this to be as valuable as
reported by other groups.25 We are currently studying
whether pressure gradients will be useful in selecting
those who need treatment.
Only few studies have randomised patients to
different treatments.10,23 Randomised studies with
strict inclusion criteria are needed for both short-
and especially also long-term comparisons of endo-
vascular treatment with ‘only’ medical treatment for
‘success’, morbidity and mortality. In this analysis of a
single-centre experience, it seems as endovascular
treatment compared with open revascularisation gives
at least equal results concerning hypertension and
renal function, but the finding of a reduced procedural
and long-term morbidity/mortality for endovascular
treatment makes it the first line of treatment.
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